The global Adalimumab Humira and Biosimilar market was valued at US$ 23070 million in 2022 and is projected to reach US$ 16210 million by 2029, at a CAGR of -4.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The expiration of patents for adalimumab Humira has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor TNF blocker that reduces the effects of a substance in the body that can cause inflammation.
This report aims to provide a comprehensive presentation of the global market for Adalimumab Humira and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Humira and Biosimilar. This report contains market size and forecasts of Adalimumab Humira and Biosimilar in global, including the following market information:
Global Adalimumab Humira and Biosimilar Market Revenue, 2018-2023, 2024-2029, $ millions
Global Adalimumab Humira and Biosimilar Market Sales, 2018-2023, 2024-2029, K Units
Global top five Adalimumab Humira and Biosimilar companies in 2022 %
MARKET MONITOR GLOBAL, INC MMG has surveyed the Adalimumab Humira and Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adalimumab Humira and Biosimilar Market, by Type, 2018-2023, 2024-2029 $ Millions & K Units
Global Adalimumab Humira and Biosimilar Market Segment Percentages, by Type, 2022 %
Syringe
Pen
Global Adalimumab Humira and Biosimilar Market, by Application, 2018-2023, 2024-2029 $ Millions & K Units
Global Adalimumab Humira and Biosimilar Market Segment Percentages, by Application, 2022 %
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Global Adalimumab Humira and Biosimilar Market, By Region and Country, 2018-2023, 2024-2029 $ Millions & K Units
Global Adalimumab Humira and Biosimilar Market Segment Percentages, By Region and Country, 2022 %
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adalimumab Humira and Biosimilar revenues in global market, 2018-2023 Estimated, $ millions
Key companies Adalimumab Humira and Biosimilar revenues share in global market, 2022 %
Key companies Adalimumab Humira and Biosimilar sales in global market, 2018-2023 Estimated, K Units
Key companies Adalimumab Humira and Biosimilar sales share in global market, 2022 %
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adalimumab Humira and Biosimilar, market overview.
Chapter 2: Global Adalimumab Humira and Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Adalimumab Humira and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adalimumab Humira and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Adalimumab Humira and Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Adalimumab Humira and Biosimilar Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adalimumab Humira and Biosimilar Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adalimumab Humira and Biosimilar Overall Market Size
2.1 Global Adalimumab Humira and Biosimilar Market Size: 2022 VS 2029
2.2 Global Adalimumab Humira and Biosimilar Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Adalimumab Humira and Biosimilar Sales: 2018-2029
3 Company Landscape
3.1 Top Adalimumab Humira and Biosimilar Players in Global Market
3.2 Top Global Adalimumab Humira and Biosimilar Companies Ranked by Revenue
3.3 Global Adalimumab Humira and Biosimilar Revenue by Companies
3.4 Global Adalimumab Humira and Biosimilar Sales by Companies
3.5 Global Adalimumab Humira and Biosimilar Price by Manufacturer 2018-2023
3.6 Top 3 and Top 5 Adalimumab Humira and Biosimilar Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Adalimumab Humira and Biosimilar Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adalimumab Humira and Biosimilar Players in Global Market
3.8.1 List of Global Tier 1 Adalimumab Humira and Biosimilar Companies
3.8.2 List of Global Tier 2 and Tier 3 Adalimumab Humira and Biosimilar Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Adalimumab Humira and Biosimilar Market Size Markets, 2022 & 2029
4.1.2 Syringe
4.1.3 Pen
4.2 By Type - Global Adalimumab Humira and Biosimilar Revenue & Forecasts
4.2.1 By Type - Global Adalimumab Humira and Biosimilar Revenue, 2018-2023
4.2.2 By Type - Global Adalimumab Humira and Biosimilar Revenue, 2024-2029
4.2.3 By Type - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
4.3 By Type - Global Adalimumab Humira and Biosimilar Sales & Forecasts
4.3.1 By Type - Global Adalimumab Humira and Biosimilar Sales, 2018-2023
4.3.2 By Type - Global Adalimumab Humira and Biosimilar Sales, 2024-2029
4.3.3 By Type - Global Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
4.4 By Type - Global Adalimumab Humira and Biosimilar Price Manufacturers Selling Prices, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adalimumab Humira and Biosimilar Market Size, 2022 & 2029
5.1.2 Ankylosing Spondylitis
5.1.3 Rheumatoid Arthritis
5.1.4 Crohn’s Disease
5.1.5 Other
5.2 By Application - Global Adalimumab Humira and Biosimilar Revenue & Forecasts
5.2.1 By Application - Global Adalimumab Humira and Biosimilar Revenue, 2018-2023
5.2.2 By Application - Global Adalimumab Humira and Biosimilar Revenue, 2024-2029
5.2.3 By Application - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
5.3 By Application - Global Adalimumab Humira and Biosimilar Sales & Forecasts
5.3.1 By Application - Global Adalimumab Humira and Biosimilar Sales, 2018-2023
5.3.2 By Application - Global Adalimumab Humira and Biosimilar Sales, 2024-2029
5.3.3 By Application - Global Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
5.4 By Application - Global Adalimumab Humira and Biosimilar Price Manufacturers Selling Prices, 2018-2029
6 Sights by Region
6.1 By Region - Global Adalimumab Humira and Biosimilar Market Size, 2022 & 2029
6.2 By Region - Global Adalimumab Humira and Biosimilar Revenue & Forecasts
6.2.1 By Region - Global Adalimumab Humira and Biosimilar Revenue, 2018-2023
6.2.2 By Region - Global Adalimumab Humira and Biosimilar Revenue, 2024-2029
6.2.3 By Region - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
6.3 By Region - Global Adalimumab Humira and Biosimilar Sales & Forecasts
6.3.1 By Region - Global Adalimumab Humira and Biosimilar Sales, 2018-2023
6.3.2 By Region - Global Adalimumab Humira and Biosimilar Sales, 2024-2029
6.3.3 By Region - Global Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Adalimumab Humira and Biosimilar Revenue, 2018-2029
6.4.2 By Country - North America Adalimumab Humira and Biosimilar Sales, 2018-2029
6.4.3 US Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.4.4 Canada Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.4.5 Mexico Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Adalimumab Humira and Biosimilar Revenue, 2018-2029
6.5.2 By Country - Europe Adalimumab Humira and Biosimilar Sales, 2018-2029
6.5.3 Germany Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5.4 France Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5.5 U.K. Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5.6 Italy Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5.7 Russia Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5.8 Nordic Countries Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.5.9 Benelux Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Adalimumab Humira and Biosimilar Revenue, 2018-2029
6.6.2 By Region - Asia Adalimumab Humira and Biosimilar Sales, 2018-2029
6.6.3 China Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.6.4 Japan Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.6.5 South Korea Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.6.6 Southeast Asia Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.6.7 India Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Adalimumab Humira and Biosimilar Revenue, 2018-2029
6.7.2 By Country - South America Adalimumab Humira and Biosimilar Sales, 2018-2029
6.7.3 Brazil Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.7.4 Argentina Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Adalimumab Humira and Biosimilar Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Adalimumab Humira and Biosimilar Sales, 2018-2029
6.8.3 Turkey Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.8.4 Israel Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.8.5 Saudi Arabia Adalimumab Humira and Biosimilar Market Size, 2018-2029
6.8.6 UAE Adalimumab Humira and Biosimilar Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Adalimumab Humira and Biosimilar Major Product Offerings
7.1.4 AbbVie Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.1.5 AbbVie Key News & Latest Developments
7.2 Eisai
7.2.1 Eisai Company Summary
7.2.2 Eisai Business Overview
7.2.3 Eisai Adalimumab Humira and Biosimilar Major Product Offerings
7.2.4 Eisai Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.2.5 Eisai Key News & Latest Developments
7.3 Cadila Healthcare
7.3.1 Cadila Healthcare Company Summary
7.3.2 Cadila Healthcare Business Overview
7.3.3 Cadila Healthcare Adalimumab Humira and Biosimilar Major Product Offerings
7.3.4 Cadila Healthcare Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.3.5 Cadila Healthcare Key News & Latest Developments
7.4 Torrent Pharmaceuticals
7.4.1 Torrent Pharmaceuticals Company Summary
7.4.2 Torrent Pharmaceuticals Business Overview
7.4.3 Torrent Pharmaceuticals Adalimumab Humira and Biosimilar Major Product Offerings
7.4.4 Torrent Pharmaceuticals Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.4.5 Torrent Pharmaceuticals Key News & Latest Developments
7.5 Amgen
7.5.1 Amgen Company Summary
7.5.2 Amgen Business Overview
7.5.3 Amgen Adalimumab Humira and Biosimilar Major Product Offerings
7.5.4 Amgen Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.5.5 Amgen Key News & Latest Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Summary
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Adalimumab Humira and Biosimilar Major Product Offerings
7.6.4 Boehringer Ingelheim Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.6.5 Boehringer Ingelheim Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Adalimumab Humira and Biosimilar Major Product Offerings
7.7.4 Novartis Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.7.5 Novartis Key News & Latest Developments
7.8 Samsung Bioepis
7.8.1 Samsung Bioepis Company Summary
7.8.2 Samsung Bioepis Business Overview
7.8.3 Samsung Bioepis Adalimumab Humira and Biosimilar Major Product Offerings
7.8.4 Samsung Bioepis Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.8.5 Samsung Bioepis Key News & Latest Developments
7.9 Viatris
7.9.1 Viatris Company Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Adalimumab Humira and Biosimilar Major Product Offerings
7.9.4 Viatris Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.9.5 Viatris Key News & Latest Developments
7.10 Pfizer
7.10.1 Pfizer Company Summary
7.10.2 Pfizer Business Overview
7.10.3 Pfizer Adalimumab Humira and Biosimilar Major Product Offerings
7.10.4 Pfizer Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.10.5 Pfizer Key News & Latest Developments
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Company Summary
7.11.2 Fresenius Kabi Adalimumab Humira and Biosimilar Business Overview
7.11.3 Fresenius Kabi Adalimumab Humira and Biosimilar Major Product Offerings
7.11.4 Fresenius Kabi Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.11.5 Fresenius Kabi Key News & Latest Developments
7.12 Coherus
7.12.1 Coherus Company Summary
7.12.2 Coherus Adalimumab Humira and Biosimilar Business Overview
7.12.3 Coherus Adalimumab Humira and Biosimilar Major Product Offerings
7.12.4 Coherus Adalimumab Humira and Biosimilar Sales and Revenue in Global 2018-2023
7.12.5 Coherus Key News & Latest Developments
8 Global Adalimumab Humira and Biosimilar Production Capacity, Analysis
8.1 Global Adalimumab Humira and Biosimilar Production Capacity, 2018-2029
8.2 Adalimumab Humira and Biosimilar Production Capacity of Key Manufacturers in Global Market
8.3 Global Adalimumab Humira and Biosimilar Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Adalimumab Humira and Biosimilar Supply Chain Analysis
10.1 Adalimumab Humira and Biosimilar Industry Value Chain
10.2 Adalimumab Humira and Biosimilar Upstream Market
10.3 Adalimumab Humira and Biosimilar Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Adalimumab Humira and Biosimilar Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
List of Tables
Table 1. Key Players of Adalimumab Humira and Biosimilar in Global Market
Table 2. Top Adalimumab Humira and Biosimilar Players in Global Market, Ranking by Revenue 2022
Table 3. Global Adalimumab Humira and Biosimilar Revenue by Companies, US$, Mn, 2018-2023
Table 4. Global Adalimumab Humira and Biosimilar Revenue Share by Companies, 2018-2023
Table 5. Global Adalimumab Humira and Biosimilar Sales by Companies, K Units, 2018-2023
Table 6. Global Adalimumab Humira and Biosimilar Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Adalimumab Humira and Biosimilar Price 2018-2023 & US$/Unit
Table 8. Global Manufacturers Adalimumab Humira and Biosimilar Product Type
Table 9. List of Global Tier 1 Adalimumab Humira and Biosimilar Companies, Revenue US$, Mn in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adalimumab Humira and Biosimilar Companies, Revenue US$, Mn in 2022 and Market Share
Table 11. By Type – Global Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2022 & 2029
Table 12. By Type - Global Adalimumab Humira and Biosimilar Revenue US$, Mn, 2018-2023
Table 13. By Type - Global Adalimumab Humira and Biosimilar Revenue US$, Mn, 2024-2029
Table 14. By Type - Global Adalimumab Humira and Biosimilar Sales K Units, 2018-2023
Table 15. By Type - Global Adalimumab Humira and Biosimilar Sales K Units, 2024-2029
Table 16. By Application – Global Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2022 & 2029
Table 17. By Application - Global Adalimumab Humira and Biosimilar Revenue US$, Mn, 2018-2023
Table 18. By Application - Global Adalimumab Humira and Biosimilar Revenue US$, Mn, 2024-2029
Table 19. By Application - Global Adalimumab Humira and Biosimilar Sales K Units, 2018-2023
Table 20. By Application - Global Adalimumab Humira and Biosimilar Sales K Units, 2024-2029
Table 21. By Region – Global Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2022 VS 2029
Table 22. By Region - Global Adalimumab Humira and Biosimilar Revenue US$, Mn, 2018-2023
Table 23. By Region - Global Adalimumab Humira and Biosimilar Revenue US$, Mn, 2024-2029
Table 24. By Region - Global Adalimumab Humira and Biosimilar Sales K Units, 2018-2023
Table 25. By Region - Global Adalimumab Humira and Biosimilar Sales K Units, 2024-2029
Table 26. By Country - North America Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2023
Table 27. By Country - North America Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2024-2029
Table 28. By Country - North America Adalimumab Humira and Biosimilar Sales, K Units, 2018-2023
Table 29. By Country - North America Adalimumab Humira and Biosimilar Sales, K Units, 2024-2029
Table 30. By Country - Europe Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2023
Table 31. By Country - Europe Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2024-2029
Table 32. By Country - Europe Adalimumab Humira and Biosimilar Sales, K Units, 2018-2023
Table 33. By Country - Europe Adalimumab Humira and Biosimilar Sales, K Units, 2024-2029
Table 34. By Region - Asia Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2023
Table 35. By Region - Asia Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2024-2029
Table 36. By Region - Asia Adalimumab Humira and Biosimilar Sales, K Units, 2018-2023
Table 37. By Region - Asia Adalimumab Humira and Biosimilar Sales, K Units, 2024-2029
Table 38. By Country - South America Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2023
Table 39. By Country - South America Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2024-2029
Table 40. By Country - South America Adalimumab Humira and Biosimilar Sales, K Units, 2018-2023
Table 41. By Country - South America Adalimumab Humira and Biosimilar Sales, K Units, 2024-2029
Table 42. By Country - Middle East & Africa Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2023
Table 43. By Country - Middle East & Africa Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2024-2029
Table 44. By Country - Middle East & Africa Adalimumab Humira and Biosimilar Sales, K Units, 2018-2023
Table 45. By Country - Middle East & Africa Adalimumab Humira and Biosimilar Sales, K Units, 2024-2029
Table 46. AbbVie Company Summary
Table 47. AbbVie Adalimumab Humira and Biosimilar Product Offerings
Table 48. AbbVie Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 49. AbbVie Key News & Latest Developments
Table 50. Eisai Company Summary
Table 51. Eisai Adalimumab Humira and Biosimilar Product Offerings
Table 52. Eisai Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 53. Eisai Key News & Latest Developments
Table 54. Cadila Healthcare Company Summary
Table 55. Cadila Healthcare Adalimumab Humira and Biosimilar Product Offerings
Table 56. Cadila Healthcare Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 57. Cadila Healthcare Key News & Latest Developments
Table 58. Torrent Pharmaceuticals Company Summary
Table 59. Torrent Pharmaceuticals Adalimumab Humira and Biosimilar Product Offerings
Table 60. Torrent Pharmaceuticals Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 61. Torrent Pharmaceuticals Key News & Latest Developments
Table 62. Amgen Company Summary
Table 63. Amgen Adalimumab Humira and Biosimilar Product Offerings
Table 64. Amgen Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 65. Amgen Key News & Latest Developments
Table 66. Boehringer Ingelheim Company Summary
Table 67. Boehringer Ingelheim Adalimumab Humira and Biosimilar Product Offerings
Table 68. Boehringer Ingelheim Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 69. Boehringer Ingelheim Key News & Latest Developments
Table 70. Novartis Company Summary
Table 71. Novartis Adalimumab Humira and Biosimilar Product Offerings
Table 72. Novartis Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 73. Novartis Key News & Latest Developments
Table 74. Samsung Bioepis Company Summary
Table 75. Samsung Bioepis Adalimumab Humira and Biosimilar Product Offerings
Table 76. Samsung Bioepis Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 77. Samsung Bioepis Key News & Latest Developments
Table 78. Viatris Company Summary
Table 79. Viatris Adalimumab Humira and Biosimilar Product Offerings
Table 80. Viatris Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 81. Viatris Key News & Latest Developments
Table 82. Pfizer Company Summary
Table 83. Pfizer Adalimumab Humira and Biosimilar Product Offerings
Table 84. Pfizer Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 85. Pfizer Key News & Latest Developments
Table 86. Fresenius Kabi Company Summary
Table 87. Fresenius Kabi Adalimumab Humira and Biosimilar Product Offerings
Table 88. Fresenius Kabi Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 89. Fresenius Kabi Key News & Latest Developments
Table 90. Coherus Company Summary
Table 91. Coherus Adalimumab Humira and Biosimilar Product Offerings
Table 92. Coherus Adalimumab Humira and Biosimilar Sales K Units, Revenue US$, Mn and Average Price US$/Unit 2018-2023
Table 93. Coherus Key News & Latest Developments
Table 94. Adalimumab Humira and Biosimilar Production Capacity K Units of Key Manufacturers in Global Market, 2021-2023 K Units
Table 95. Global Adalimumab Humira and Biosimilar Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global Adalimumab Humira and Biosimilar Production by Region, 2018-2023 K Units
Table 97. Global Adalimumab Humira and Biosimilar Production by Region, 2024-2029 K Units
Table 98. Adalimumab Humira and Biosimilar Market Opportunities & Trends in Global Market
Table 99. Adalimumab Humira and Biosimilar Market Drivers in Global Market
Table 100. Adalimumab Humira and Biosimilar Market Restraints in Global Market
Table 101. Adalimumab Humira and Biosimilar Raw Materials
Table 102. Adalimumab Humira and Biosimilar Raw Materials Suppliers in Global Market
Table 103. Typical Adalimumab Humira and Biosimilar Downstream
Table 104. Adalimumab Humira and Biosimilar Downstream Clients in Global Market
Table 105. Adalimumab Humira and Biosimilar Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Adalimumab Humira and Biosimilar Segment by Type in 2022
Figure 2. Adalimumab Humira and Biosimilar Segment by Application in 2022
Figure 3. Global Adalimumab Humira and Biosimilar Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Adalimumab Humira and Biosimilar Market Size: 2022 VS 2029 US$, Mn
Figure 6. Global Adalimumab Humira and Biosimilar Revenue, 2018-2029 US$, Mn
Figure 7. Adalimumab Humira and Biosimilar Sales in Global Market: 2018-2029 K Units
Figure 8. The Top 3 and 5 Players Market Share by Adalimumab Humira and Biosimilar Revenue in 2022
Figure 9. By Type - Global Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2022 & 2029
Figure 10. By Type - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 11. By Type - Global Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 12. By Type - Global Adalimumab Humira and Biosimilar Price US$/Unit, 2018-2029
Figure 13. By Application - Global Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2022 & 2029
Figure 14. By Application - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 15. By Application - Global Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 16. By Application - Global Adalimumab Humira and Biosimilar Price US$/Unit, 2018-2029
Figure 17. By Region - Global Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2022 & 2029
Figure 18. By Region - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 20. By Region - Global Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 21. By Country - North America Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 22. By Country - North America Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 23. US Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 24. Canada Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 25. Mexico Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 26. By Country - Europe Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 28. Germany Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 29. France Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 30. U.K. Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 31. Italy Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 32. Russia Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 33. Nordic Countries Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 34. Benelux Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 35. By Region - Asia Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 37. China Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 38. Japan Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 39. South Korea Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 40. Southeast Asia Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 41. India Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 42. By Country - South America Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 43. By Country - South America Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 44. Brazil Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 45. Argentina Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 46. By Country - Middle East & Africa Adalimumab Humira and Biosimilar Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Adalimumab Humira and Biosimilar Sales Market Share, 2018-2029
Figure 48. Turkey Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 49. Israel Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 50. Saudi Arabia Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 51. UAE Adalimumab Humira and Biosimilar Revenue, US$, Mn, 2018-2029
Figure 52. Global Adalimumab Humira and Biosimilar Production Capacity K Units, 2018-2029
Figure 53. The Percentage of Production Adalimumab Humira and Biosimilar by Region, 2022 VS 2029
Figure 54. Adalimumab Humira and Biosimilar Industry Value Chain
Figure 55. Marketing Channels
